Cytotoxic Cell Function in Bronchogenic Carcinoma

Kratikanont, P; Shazo, Richard de; Banks, Daniel E.; Chapman, Yvonne

doi:10.1378/chest.92.1.90

Cited by 11 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LAK cells were generated by incubation (5 days, 37°C, 5% CO 2 ) of PBM with recombinant human interleukin-2 (IL-2) (1,000 U·mL -1 ) [20]. The effectiveness of this procedure was repeatedly checked by testing the ability of the generated LAK cells to exert cytotoxic activity on the NK-resistant A-549 type-II pneumocyte cell line (ATCC) [21].…”

Section: Generation Of Lak Cellsmentioning

confidence: 99%

ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells

Melis¹,

Spatafora²,

Melodia³

et al. 1996

Eur Respir J

View full text Add to dashboard Cite

show abstract

Section: Generation Of Lak Cellsmentioning

confidence: 99%

ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells

Melis¹,

Spatafora²,

Melodia³

et al. 1996

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…et al9 examined LAK activity against two lung tumor cells IL-?-activated cytotoxicity of lymphocytes from patients in different stages of disease. Patients were divided into groups according to their extent of disease.…”

mentioning

confidence: 99%

In vitro natural killer and lymphokine-activated killer activity in patients with bronchogenic carcinoma

Dunlap

Lane

Cloud

et al. 1990

Cancer

View full text Add to dashboard Cite

The authors examined peripheral blood mononuclear cells from 45 patients with bronchogenic carcinoma to determine natural killer (NK) and lymphokine-activated killer (LAK) activity after in vitro incubation with media alone or media plus interferon gamma (IFN, 200 U/ml) and/or interleukin-2 (IL-2, 100 U/ml). Our results show that lymphocytes from patients with bronchogenic carcinoma can acquire LAK activity, but the level of activity acquired was significantly lower compared with lymphocytes from 25 control subjects when IL-2 cultures were supplemented with 10% autologous human serum (AHS) (15.6% +/- 2.1% specific release versus 26.0% +/- 2.9% specific release, P = 0.004). The LAK activity, defined as cytotoxicity of an NK-resistant cell line, of the patients' lymphocytes was augmented when cells were cultured with both IL-2 and IFN compared with IL-2 alone (P = 0.0001, paired t-test). Control subjects were unchanged (P = 0.09). There was no significant difference between groups of patients with different histologic types of tumor or different stages of disease. The NK activity, defined as killing of NK-sensitive K-562 target cells, of the patients' lymphocytes was not significantly different from that of the controls' lymphocytes (42.8% +/- 3.0% specific release versus 49.3% +/- 3.3% specific release, P = 0.16). These studies indicate the feasibility of IL-2 and IFN therapy in patients with bronchogenic carcinoma.

show abstract

Therapeutic Approaches to Cancer-Associated Immune Suppression

Oldham

1998

Principles of Cancer Biotherapy

View full text Add to dashboard Cite

Cytotoxic Cell Function in Bronchogenic Carcinoma

Cited by 11 publications

References 14 publications

ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells

ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells

In vitro natural killer and lymphokine-activated killer activity in patients with bronchogenic carcinoma

Therapeutic Approaches to Cancer-Associated Immune Suppression

Contact Info

Product

Resources

About